quinolinic acid has been researched along with Irritable Bowel Syndrome in 1 studies
Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.
pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.
quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.
Irritable Bowel Syndrome: A disorder with chronic or recurrent colonic symptoms without a clearcut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our objectives are to demonstrate whether the kynurenine pathway is activated in diarrhea-type irritable bowel syndrome (IBS-D) patients, and whether the neurotoxic metabolite quinolinic acid (QUIN) is out of balance with the neuroprotective metabolite kynurenic acid (KYNA), and further explore whether this can lead to increase of N-methyl D-aspartate receptor 2B (NMDAR2B) expression in the enteric nervous system and in turn leads to intestinal symptoms and mood disorders." | 7.96 | Characterization of kynurenine pathway in patients with diarrhea-predominant irritable bowel syndrome. ( Bai, Y; Cui, Z; Li, P; Li, Y; Wang, D; Wang, Y; Zhang, J; Zheng, J, 2020) |
| "Our objectives are to demonstrate whether the kynurenine pathway is activated in diarrhea-type irritable bowel syndrome (IBS-D) patients, and whether the neurotoxic metabolite quinolinic acid (QUIN) is out of balance with the neuroprotective metabolite kynurenic acid (KYNA), and further explore whether this can lead to increase of N-methyl D-aspartate receptor 2B (NMDAR2B) expression in the enteric nervous system and in turn leads to intestinal symptoms and mood disorders." | 3.96 | Characterization of kynurenine pathway in patients with diarrhea-predominant irritable bowel syndrome. ( Bai, Y; Cui, Z; Li, P; Li, Y; Wang, D; Wang, Y; Zhang, J; Zheng, J, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, P | 1 |
| Zheng, J | 1 |
| Bai, Y | 1 |
| Wang, D | 1 |
| Cui, Z | 1 |
| Li, Y | 1 |
| Zhang, J | 1 |
| Wang, Y | 1 |
1 other study available for quinolinic acid and Irritable Bowel Syndrome
| Article | Year |
|---|---|
Characterization of kynurenine pathway in patients with diarrhea-predominant irritable bowel syndrome.
Topics: Diarrhea; Female; Humans; Intestinal Mucosa; Irritable Bowel Syndrome; Kynurenic Acid; Kynurenine; M | 2020 |